AbbVie Gains But Lags Market: What You Should Know


2019-07-16 05:45:09 YAHOO!FINANCE


AbbVie closed the most recent trading day at $70.29, moving +0.01% from the previous trading session. This move lagged the S&P 500's daily gain of 0.02%. Elsewhere, the Dow gained 0.1%, while the tech-heavy Nasdaq added 0.17%. Coming into today, shares of the drugmaker had lost 10.98% in the past month. In that same time, the Medical sector lost 0.79%, while the S&P 500 gained 4.82%. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. This is expected to be July 26, 2019. On that day, ABBV is projected to report earnings of $2.21 per share, which would represent year-over-year growth of 10.5%. Our most recent consensus estimate is calling for quarterly revenue of $8.09 billion, down 2.27% from the year-ago period. For the full year, our Zacks Consensus Estimates are projecting earnings of $8.78 per share and revenue of $32.79 billion, which would represent changes of +11% and +0.11%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for ABBV. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.39% lower. ABBV currently has a Zacks Rank of #3 (Hold). In terms of valuation, ABBV is currently trading at a Forward P/E ratio of 8.01. This represents a discount compared to its industry's average Forward P/E of 14.3. It is also worth noting that ABBV currently has a PEG ratio of 1.44. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.09 based on yesterday's closing prices. The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 33, putting it in the top 13% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on click here.
艾伯维(AbbVie)最近一个交易日收盘报70.29美元,较前一交易日上涨0.01%。这一举措落后于标普500指数0.02%的日涨幅。在其他地区,道琼斯指数上涨了0.1%,而科技股云集的纳斯达克指数上涨了0.17%。 进入今天,制药商的股价在过去一个月下跌了10.98%。与此同时,医疗板块下跌0.79%,标准普尔500指数上涨4.82%。 华尔街将从荷兰银行( ABBV )寻找积极的一面,因为它将接近下一个收益报告日。预计2019年7月26日。当天,预计 ABBV 的每股收益为2.21美元,同比增长10.5%。我们最近的共识估计是,季度收入为80.9亿美元,较上年同期下降2.27%。 我们的 Zacks 一致估计全年预测每股收益为8.78美元,收入为327.9亿美元,分别较上年变动+11%和+0.11%。 投资者还应注意 ABBV 分析师估计的近期变化。最近的修订往往反映了近期的商业趋势。因此,我们可以将正面估计修订解读为公司经营前景的良好标志。 研究表明,这些估计修正与近期股价走势直接相关。为了从中获益,我们开发了 ZackRank ,一种考虑到这些估计更改并提供可操作的评级系统的专有模型。 Zacks 排名系统范围从#1(强劲购买)到#5(强劲销售)。这是一项卓越的、外部审计的成功记录,自1988年以来,#1股票的年平均回报率为+25%。在过去30天内,我们一致认为的 EPS 预测下降了0.39%。ABBV 目前拥有 Zacks 排名第三(持有)。 就估值而言, ABBV 目前的远期市盈率为8.01倍。与行业平均远期 P / E 14.3相比,这是一个折扣。 值得注意的是, ABBV 目前的 PEG 比率为1.44。PEG 比率与广泛使用的市盈率类似,但该指标也考虑了公司的预期盈利增长率。按昨日收盘价计算,大盘股平均持有 PEG 比率为2.09。 大盘股药业是医疗板块的一部分。该集团的 Zacks 行业排名为33,在所有250多个行业中排名前13%。 Zacks 行业排名通过衡量集团内单个股票的平均 Zacks 排名来衡量我们行业集团的实力。我们的研究表明,排名前50%的行业表现优于排名后半的行业,表现为2比1。 一定要遵循所有这些股票移动的指标,以及更多的 Zacks 。com 。 想要 Zacks 投资研究公司的最新建议吗?今天,你可以下载7个最佳股票的未来30天。点击获取此免费报告艾伯维(AbbVie)公司( ABBV ):免费股票分析报告阅读本文关于 Zacks 。com 点击这里。